Biotech News
Fulgent Reports Third Quarter 2026 Financial Results
Revenue of $90.4 million, growing approximately 8% year-over-year GAAP gross profit of $31.9 million, or GAAP gross margin of 35.3%; Non-GAAP gross profit of $32.8 million, or Non-GAAP gross margin of 36.3% GAAP loss of $13.2 million, or $(0.48) per share; Non-GAAP loss of $2.4 million, or $(0.09)